Schweizerische Eidgenossenschaft
Confédération suisse
Confederazione Svizzera
Confederaziun svizra

Swiss Confederation

Federal Department of Home Affairs DHA
Federal Office of Public Health FOPH

Federal Department of the Environment, Transport, Energy and Communications DETEC
Federal Office for the Environment FOEN

swissmedic
Swiss Agency for Therapeutic Products

Statement of GLP Compliance

According to Article 14 paragraph 3 Ordinance on Good Laboratory Practice [OGLP, SR 813.112.1]

The notification authority for chemicals confirms that the following test facility was inspected with respect to the compliance with the Swiss Ordinance on Good Laboratory Practice, adopted on 18th May 2005 [OGLP, SR 813.112.1]. This Ordinance is based on the OECD Principles of Good Laboratory Practice, as revised in 1997 and adopted on 26th November 1997 by decision of the OECD Council [C(97)186/Final].

Unequivocal name and address of the test facility:	Areas of expertise according to article 3 paragraph 1 letter d OGLP:
IBR Inc., Institute for Biopharmaceutical Research Lauchefeld 31 9548 Matzingen, Switzerland	3. mutagenicity studies, 8. analytical and clinical chemistry testing, 9. other studies, (Pharmacokinetics, Immunological Testing).

Inspection authority: Swissmedic (Swiss Agency for Therapeutic Products)

Date of inspection: 27 and 28 January 2014

Date of decision: 7 May 2014

Based on the above mentioned decision it can be confirmed that the above mentioned test facility is able to conduct studies according to the aforementioned areas of expertise in compliance with the principles of GLP. The above mentioned test facility is listed in the register and GLP list according to the Article 14 OGLP and is inspected on a regular basis according to Article 6 paragraph 2 OGLP.

Swiss Federal Office of Public Health
Consumer protection directorate
Notification authority for chemicals
CH-3003 Bern

FEDERAL OFFICE OF PUBLIC HEALTH

Bern, 11.06.2014, The Head, Dr. Pierre Favre.